A Clinical Study to Assess the Effects of Zofin in Moderate to Severe COVID-19 Patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Mar 2024 According to a ZEO ScientifiX, Inc media release, company name changed from Organicell to ZEO ScientifiX.
30 Apr 2021 New trial record
28 Apr 2021 According to an Organicell media release, if the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin in India as a therapeutic for treating COVID-19.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com